Woo Shun Lee

Dr. Woo Shun Lee


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
DLDong-Yun Lee
Dong-Yun Lee
SLSa Ra Lee
Sa Ra Lee
SKSeul Ki Kim
Seul Ki Kim
JJJongkil Joo
Jongkil Joo
WLWoo Shun Lee
Woo Shun Lee
Sung-Hoon KimSung-Hoon Kim
Sung-Hoon Kim
Lee DY, et al. Yonsei Med J. 2020 Oct;61(10):868-874. https://doi.org/10.3349/ymj.2020.61.10.868

23 August 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
HCHyewon Chung
Hyewon Chung
JPJin-Woo Park
Jin-Woo Park
DKDai Hyun Kim
Dai Hyun Kim
SSSoo-Hong Seo
Soo-Hong Seo
KKKyoung-Ah Kim
Kyoung-Ah Kim
JPJi-Young Park
Ji-Young Park
This study aimed to explore pharmacokinetics, pharmacodynamics, and safety/tolerability of MT921, an injectable cholic acid, after a single subcutaneous administration to healthy volunteers. A randomized, double-blinded, placebo-controlled, single dose-ascending phase 1 study enrolled 24 subjects who were assigned to three groups (60 mg, 120 mg, and 150 mg) of MT921. Blood samples were obtained for a 24-h period before and after injecting MT921 to the submental fat area. Plasma concentrations of cholic acid and deoxycholic acid were determined for pharmacokinetic analysis. Levels of free fatty acid, triglyceride, and total cholesterol were measured for pharmacodynamic analysis. Safety and tolerability were assessed until 21 days post-dose. While systemic exposure to cholic acid tended to increase as the MT921 dose increased, pharmacokinetic profiles of deoxycholic acid were similar among dose groups without showing significant changes. Pharmacodynamic profiles were comparable when measured at baseline and post-dose. The most frequent adverse events were injection site pain and edema. All adverse drug reactions resolved without treatment. MT921 appeared to be well-tolerated after an injection to the submental area at a dose up to 150 mg. Systemic exposure to cholic acid increased as the dose increased. Blood lipid profiles and deoxycholic acid levels were not affected by MT921 treatment.

31 July 2024 in Dermatologic Surgery
Verified
Journal Article
Closed access
WLWoo Shun Lee
Woo Shun Lee
HJHyun Ho Jung
Hyun Ho Jung
BACKGROUND: Botulinum toxin (BoNT) has evolved as a popular treatment for various medical and aesthetic conditions since the 1980s. The emergence of new liquid formulation BoNT products in the industry highlights the need to evaluate the value and advantages of these modern formulations. OBJECTIVE: The aim of this review was to assess and compare the expected difference in practice between liquid and powder formulation BoNT products. PAITENTS AND METHODS/MATERIALS: This article involves a review of pertinent guidelines, product information from manufacturers, available database for safety reports, and survey results. RESULTS: Guidelines and safety reports have pointed out potential risks in the reconstitution process, while medication preparation steps are simplified in liquid formulation. CONCLUSION: The shift toward ready-to-use liquid products can mitigate risks related with reconstitution errors and potentially enhancing patient care by saving time and cost associated with medication preparation.

3 May 2013 in Toxicon
Verified
Journal Article
Closed access
WLWoo Shun Lee
Woo Shun Lee
CWC.H. Won
C.H. Won
CHC.H. Huh
C.H. Huh
HKH. Kang
H. Kang
BKB.J. Kim
B.J. Kim
WKW.S. Kim
W.S. Kim

23 March 2025 in Toxins
Verified
Journal Article
Open access
PDF file
HHHye Sung Han
Hye Sung Han
WKWon Serk Kim
Won Serk Kim
YLYangwon Lee
Yangwon Lee
CWChong Hyun Won
Chong Hyun Won
WLWoo Shun Lee
Woo Shun Lee
Beomjoon KimBeomjoon Kim
Beomjoon Kim
MBA-P01 is a newly developed botulinum toxin A (BoNT-A) product designed to provide similar clinical effects as OnabotulinumtoxinA (ONA-BoNT-A), thereby providing an alternative treatment option for glabellar lines. It is another holotoxin preparation containing BoNT-A1. This randomized, double-blind, active-controlled, multi-center, Phase III clinical trial aimed to evaluate the efficacy and safety of MBA-P01 compared with OnabotulinumtoxinA (ONA-BoNT-A). In total, 318 participants were enrolled and received 20 units of MBA-P01 or ONA-BoNT-A on the forehead and glabella. At the 4-week assessment, the primary endpoint revealed no significant difference in the improvement rate of glabellar wrinkles between the two groups, confirming the non-inferiority of MBA-P01 to ONA-BoNT-A. Furthermore, some evaluation variables showed higher improvement rates for MBA-P01 than for ONA-BoNT-A. Adverse reactions and other safety analysis results were considered acceptable. Interestingly, a subgroup analysis of patients with the coronavirus disease (COVID-19) showed that the duration of BoNT-A treatment was shorter among those who contracted COVID-19 after BoNT-A treatment compared with those who have not. The limitations of this study include the predominance of female participants and the exclusive enrollment of Korean patients. MBA-P01 is expected to be clinically useful in terms of the efficient and safe reduction of glabellar wrinkles, which will provide patients with additional treatment options.

7 November 2019 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
YLYoungkyoung Lim
Youngkyoung Lim
JLJong Hee Lee
Jong Hee Lee
WLWoo Shun Lee
Woo Shun Lee
WLWeon Ju Lee
Weon Ju Lee
Hei Sung KimHei Sung Kim
Hei Sung Kim
Chang-Hun HuhChang-Hun Huh
Chang-Hun Huh
Neuronox® has not yet been investigated for its efficacy and safety in the treatment of lateral canthal lines (LCL).This study was a randomized, double-blind, active drug controlled, multicenter, 1...